Physician profile
Alla Boykoff
NPI 1629167747
$20,815.37
in general payments reported to CMS, 2019-2025
52 companies · $3,621 in 2025
The $3,621 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,003 · 2020: $1,852 · 2021: $2,700 · 2022: $2,857 · 2023: $3,239 · 2024: $3,542 · 2025: $3,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $38.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,364.05 |
| Education | $38.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,786.92 | 2019-2025 | Qulipta, Linzess, Vraylar |
| Novo Nordisk INC | $1,724.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,607.23 | 2019-2025 | Jardiance |
| Pfizer INC. | $1,535.55 | 2019-2025 | |
| Lilly USA, LLC | $1,350.61 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,275.00 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $808.98 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $641.93 | 2019-2025 | Prolia, Evenity, Otezla |
| Ironwood Pharmaceuticals, INC | $637.54 | 2019-2024 | Linzess |
| Allergan, INC. | $625.54 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $509.28 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $502.97 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $498.40 | 2019-2024 | Xifaxan, Trulance |
| Almatica Pharma LLC | $409.73 | 2021-2025 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $402.10 | 2019-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alla Boykoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.